Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study

World Journal of Biological Psychiatry

Volumn 11, Issue 7, 2010, Pages 894-903

  Bitter, Istvan ^a   Treuer, Tamás ^b   Dilbaz, Nesrin ^c   Oyffe, Igor ^d   Ciorabai, Eda M ^e   Gonzalez, Severiano L ^f   Ruschel, Sandra ^g   Salburg, Jolanta ^b   Dyachkova, Yulia ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b ELI LILLY AND COMPANY   (United States)

^c ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^d LEV HASHARON MENTAL HEALTH CENTER   (Israel)

^e Spitalul Judetean Constanta ^*  (Russian Federation)

^f Dr Martinez Col Doctores   (Mexico)

^g Serviço de Urologia Hospital Mário Kröeff   (Brazil)

Author keywords

olanzapine; oral conventional tablet; orodispersible tablet; patient preference; Schizophrenia

Indexed keywords

OLANZAPINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG PREFERENCE; DRUG SAFETY; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; STRUCTURED QUESTIONNAIRE; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY WEIGHT; CHOICE BEHAVIOR; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT PARTICIPATION; PATIENT SATISFACTION; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 77957129707     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2010.505663     Document Type: Article

References (46)

1. Adewuya AO, Ola BA, Mosaku SK, Fatoye FO, Eegunranti AB. 2006. Attitude towards antipsychotics among out-patients with schizophrenia in Nigeria. Acta Psychiatr Scand 113: 207-211.
2. Allain H, Bentu é-Ferrer D, Breton S, Polard E, Gandon JM. 2003. Preference of insomniac patients between a single dose of zolpidem 10 mg versus zaleplon 10 mg. Hum Psychophar-macol 18:369-374.
3. American Psychiatric Association. 1994. DSM-IV. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association.
4. American Psychiatric Association. 2000. DSM-IV-TR. Diagnostic and statistical manual of mental disorders. 4th ed. A text revision, Washington, DC: American Psychiatric Association.
5. Bergstrom RF, Mitchell M, Witcher J, Houston, J, Hill A, Taylor C, et al. 2004. Rapid onset of absorption with olan-zapine orally disintegrating tablets. J Emerg Nurs 30(5):416-417.
6. Bitter I, Treuer T, Dyachkova Y, Martenyi F, McBride MS, Ungvari GS. 2008. Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Neuropsychopharmacol 18:170-180.
7. Bobon D, Woggon B, Association for Methodology and Documentation in Psychiatry. 1986. The AMDP-system in clinical psychopharmacology. Br J Psychiatry 148:467-468.
8. Chilvers C, Dewey M, Fielding K, Gretton V, Miller P, Palmer B, et al. 2001. Antidepressant drugs and generic counselling for treatment of major depression in primary care: randomised trial with patient preference arms. Br Med J 322:772-775.
9. Czekalla J, Wagner T, Schacht A, Kluge M, Kinon B. 2007. Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients. Patient Prefer Adherence 1:19-27.
10. Dardennes R, Chartier F, Heurtebize N, Olivier V, Perrin E. 2004. Naturalistic use of the orally disintegrating tablet formulation of olanzapine in acute schizophrenic patients: An observational prospective study. Int J Neuropsychopharmacol 7 (Suppl. 2): P01.389.
11. Day JC, Bentall RP, Roberts C, Randall F, Rogers A, Cattell D, et al. 2005. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry 62:717-724.
12. Dilbaz N, Karamustafalioglu O, Oral T, Ö nder E, Cetin M. 2006. Evaluation of compliance to treatment and factors affecting compliance for schizophrenia outpatients (in Turkish). Bull Clin Psychopharmacol 16:223-232.
13. Dossenbach M, Pecenak J, Szulc A, Irimia V, Anders M, Logozar-Perkovic D, et al. 2008. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study. J Clin Psychiatry 69:1901-1915.
14. Dowson AJ, Almqvist P. 2005. The convenience of, and patient preference for, zolmitriptan orally disintegrating tablet. Curr Med Res Opin 21(Suppl 3):13-17.
15. Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC. 2004. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry 65:1372-1376.
16. Gift AG. 1989. Visual analogue scales: measurement of subjective phenomena. Nurs Res 38:286-288.
17. Guy W. 1976. Clinical Global Impressions ECDEU Assessment manual for psychopharmacology. Revised (DHEW Publ. No. ADM 76-338). Rockville, MD: National Institute of Mental Health/Bethesda, MD: US Department of Health Education, and Welfare. p. 217-222.
18. Heres S, Schmitz FS, Leucht S, Pajonk FG. 2007. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol 22:275-282.
19. Hofer A, Kemmler G, Eder U, Honeder M, Hummer M, Fleischhacker W W. 2002. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry 63:49-53.
20. Hogan TP, Awad AG, Eastwood R. 1983. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 13:177-183.
21. Howard L, Thornicroft G. 2006. Patient preference randomised controlled trials in mental health research. Br J Psychiatry 188: 303-304.
22. Jahng KH, Martin LR, Golin CE, DiMatteo MR. 2005. Preferences for medical collaboration: patient-physician congruence and patient outcomes. Patient Educ Couns 57:308-314.
23. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IPM, et al. 2008. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform dis order: an open randomised clinical trial. Lancet 371:1085-1097.
24. Karagianis J, Hoffmann VP, Arranz B, Treuer T, Maguire GA, de Haan L, et al. 2008. Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain. Hum Psychopharmacol 23:275-281.
25. Kassirer JP. 1994. Incorporating patients ' preferences into medical decisions. New Engl J Med 330:1895-1896.
26. Kinon BJ, Hill AL, Liu H, Kollack-Walker S. 2003. Olanzapine orally disintegrating tablets in the treatment of acutely ill, non-compliant patients with schizophrenia. Int JNeuropsychophar-macol 6:97-102.
27. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. 2009. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2:152-163.
28. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 353:1209-1223.
29. McKay JR, Alterman AI, McLellan T, Snider EC, O ' Brien CP. 1995. Effect of random versus nonrandom assignment in a comparison of inpatient and day hospital rehabilitation for male alcoholics. J Consult Clin Psychol 63:70-78.
30. Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA. 2008. Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr Bull 35: 336-346.
31. Müller MJ. 2006. Attitudes toward different formulations of psy-chotropic drugs: the view of patients and healthcare providers. Am J Drug Delivery 4(1):33-41.
32. Nausieda PA, Pfeiffer RF, Tagliati M, Kastenholz KV, DeRoche C, Slevin JT. 2005. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease. Clin Ther 27:58-63.
33. Novick D, Haro JM, Suarez D, Lambert M, Lépine JP, Naber D. 2007. Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study. Psy-chopharmacology 191:1015-1022.
34. Pascual JC, Pérez V, Mart ín JLR, Safont G, Puigdemont D, Álvarez E. 2007. Olanzapine orally-disintegrating tablet in severe psychotic agitation: a naturalistic study. Actas Esp Psiquiatr 35:47-51.
35. Patel MX, De Zoysa N, Bernadt M, David A. 2009. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol 23:789-796.
36. Preference Collaborative Review Group. 2008. Patients ' preferences within randomised trials: systematic review and patient level meta-analyses. Br Med J 337:a1864
37. EMEA Zyprexa Product Information. 28/07/2008 Zyprexa-H-C-115-II-92 http://www.emea.europa.eu/humandocs/PDFs/EPAR/Zyprexa/H-115-PI-en.pdf [July 3, 2009].
38. Roger A, Fortea J, Mora S, Artés M. 2008. Ebastine fast-dissolving tablets versus regular tablets: acceptability and preference in patients with allergic rhinitis. Expert Rev Clin Pharmacol 1:381-389.
39. San L, Casillas M, Ciudad A, Gilaberte I. 2008. Olanzapine orally disintegrating tablet: a review of efficacy and compliance CNS. Neurosci Ther 14:203-214.
40. Senn S. 1993. Cross-over trials in clinical research. New York: John Wiley & Sons. p. 104-109.
41. Slevin JT, Ryan M. 2006. Orally disintegrating carbidopa/levo-dopa. Future Neurol 1:139-147.
42. Steinberg SM, Venuto RC, Kuruvila CK,Taylor DO, Anil Kumar MS, Groothuis JR, et al. 2003. Randomized, open-label preference study of two cyclosporine capsule formulations (usp modified) in stable solid-organ transplant recipients. Clin Ther 25:2037-2052.
43. Street RL Jr. 2007. Aiding medical decision making: a communication perspective. Med Decis Making 27:550-553.
44. Swartz MS, Swanson JW, Wagner RH, Burns BJ, Hiday VA. 2001. Effects of involuntary outpatient commitment and depot antip-sychotics on treatment adherence in persons with severe mental illness. J Nerv Ment Dis 189:583-592.
45. Voss TC, Klapper JA. 2002. Patient preference for orally dissolving rizatriptan or zolmitriptan: a comparative, open-label, randomized, crossover trial in triptan experienced patients. Headache. 42:401-447.
46. Ward E, King M, Lloyd M, Bower P, Sibbald B, Farrelly S, et al. 2000. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression. I: clinical effectiveness. Br Med J 321:1383-1388.